Australia's largest stock trading and investment forum Australia's #1 stock forum

PER

34.1%

8.9¢ percheron therapeutics limited

Something has to change., page-253

First 253 Last

Share
Profile

Follow
Akki

35,752 Posts.

554

24/04/16

11:45

Post #: 17588984
Share

Originally posted by itsagas ↑

IMO...atl1102 is our primary drug...many here say that 15 years on the Diamond has done B/all....I say wrong...anp only got FDA approval to get atl1102 back on the road in 2005..

Home
ANTISENSE GETS APPROVAL IN GERMANY TO RESTART MS STUDY
Antisense Therapeutics has reported that the University of Essen in Germany has approved the company's application to restart the Phase IIa trial of its antisense compound, ATL1102, for patients with relapsing remitting multiple sclerosis (MS). The university will be the primary site for the clinical trial.

Patient enrollment and dosing are expected to begin in February or March. Eight other trial centers will be added in the coming months. The treatment and patient-monitoring stages of the 80-patient trial are expected to be completed by the end of 2006, assuming patient recruitment proceeds at the anticipated rate.

ATL1102 is a second-generation antisense inhibitor of an immune system protein called VLA-4 and is designed to block the synthesis of VLA-4, which is known to play a part in both the onset and progression of MS. ATL1102's mechanism of action in blocking VLA-4 is different to other drugs in development that target VLA-4 (including the monoclonal antibody Tysabri) and represents a novel therapeutic approach to the treatment of MS.

Expand

anp "only" got FDA approval to get atl1102 back on the road in 2005..

Expand

that's "only" 11 years ago

ANP Price at posting: 3.4¢ Sentiment: None Disclosure: Held
11 Upvote

0 Great analysis

Reply

Top Stories

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

What's causing the cost-of-living crisis, and how to navigate it